Therapeutic targeting of EGFR-activated metabolic pathways in glioblastoma

Phase II trial of bevacizumab and erlotinib in patients with recurrent malignant glioma

(2017) Sith Sathornsumetee et al.   NEURO-ONCOLOGY

Phase 1 trial of dasatinib plus erlotinib in adults with recurrent malignant glioma

(2012) David A. Reardon et al.   JOURNAL OF NEURO-ONCOLOGY

On-target JAK2/STAT3 inhibition slows disease progression in orthotopic xenografts of human glioblastoma brain tumor stem cells

(2012) Owen D. Stechishin et al.   NEURO-ONCOLOGY

Current clinical development of PI3K pathway inhibitors in glioblastoma

(2012) P. Y. Wen et al.   NEURO-ONCOLOGY

EGFR-Targeted Therapy in Malignant Glioma: Novel Aspects and Mechanisms of Drug Resistance

(2012) Hui-Wen Lo   Current Molecular Pharmacology

Cytoreductive surgery of glioblastoma as the key to successful adjuvant therapies: new arguments in an old discussion

(2011) Walter Stummer et al.   ACTA NEUROCHIRURGICA

Current concepts and management of glioblastoma

(2011) Matthias Preusser et al.   ANNALS OF NEUROLOGY

eEF-2 Kinase Dictates Cross-Talk between Autophagy and Apoptosis Induced by Akt Inhibition, Thereby Modulating Cytotoxicity of Novel Akt Inhibitor MK-2206

(2011) Y. Cheng et al.   CANCER RESEARCH

Phase I, Dose-Escalation Study of BKM120, an Oral Pan-Class I PI3K Inhibitor, in Patients With Advanced Solid Tumors

(2011) Johanna C. Bendell et al.   JOURNAL OF CLINICAL ONCOLOGY

PIK3CA Mutations in Patients with Advanced Cancers Treated with PI3K/AKT/mTOR Axis Inhibitors

(2011) F. Janku et al.   MOLECULAR CANCER THERAPEUTICS

A phase II trial of erlotinib in patients with recurrent malignant gliomas and nonprogressive glioblastoma multiforme postradiation therapy

(2011) J. J. Raizer et al.   NEURO-ONCOLOGY

Inhibition of PI3K/mTOR pathways in glioblastoma and implications for combination therapy with temozolomide

(2011) G. Prasad et al.   NEURO-ONCOLOGY

Perifosine and CCI 779 Co-Operate to Induce Cell Death and Decrease Proliferation in PTEN-Intact and PTEN-Deficient PDGF-Driven Murine Glioblastoma

(2011) Kenneth L. Pitter et al.   PLoS One

TLN-4601, a novel anticancer agent, inhibits Ras signaling post Ras prenylation and before MEK activation

(2010) Nadia Boufaied et al.   ANTI-CANCER DRUGS

PKI-179: An orally efficacious dual phosphatidylinositol-3-kinase (PI3K)/mammalian target of rapamycin (mTOR) inhibitor

(2010) Aranapakam M. Venkatesan et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Concurrent radiotherapy and temozolomide followed by temozolomide and sorafenib in the first-line treatment of patients with glioblastoma multiforme

(2010) John D. Hainsworth et al.   CANCER

Genetic Dissection of the Oncogenic mTOR Pathway Reveals Druggable Addiction to Translational Control via 4EBP-eIF4E

(2010) Andrew C. Hsieh et al.   CANCER CELL

Preclinical Evaluation of Radiation and Perifosine in a Genetically and Histologically Accurate Model of Brainstem Glioma

(2010) O. J. Becher et al.   CANCER RESEARCH

Reversing HOXA9 Oncogene Activation by PI3K Inhibition: Epigenetic Mechanism and Prognostic Significance in Human Glioblastoma

(2010) B. M. Costa et al.   CANCER RESEARCH

Therapeutic targeting of EGFR in malignant gliomas

(2010) Fei Ye et al.   EXPERT OPINION ON THERAPEUTIC TARGETS

Phase I/IIa Study of Cilengitide and Temozolomide With Concomitant Radiotherapy Followed by Cilengitide and Temozolomide Maintenance Therapy in Patients With Newly Diagnosed Glioblastoma

(2010) Roger Stupp et al.   JOURNAL OF CLINICAL ONCOLOGY

Antitumor Efficacy Profile of PKI-402, a Dual Phosphatidylinositol 3-Kinase/Mammalian Target of Rapamycin Inhibitor

(2010) Robert Mallon et al.   MOLECULAR CANCER THERAPEUTICS

Targeting mTOR: prospects for mTOR complex 2 inhibitors in cancer therapy

(2010) C A Sparks et al.   ONCOGENE

Automated Network Analysis Identifies Core Pathways in Glioblastoma

(2010) Ethan Cerami et al.   PLoS One

Akt and Autophagy Cooperate to Promote Survival of Drug-Resistant Glioma

(2010) Q.-W. Fan et al.   Science Signaling

Activity of a novel, dual PI3-kinase/mTor inhibitor NVP-BEZ235 against primary human pancreatic cancers grown as orthotopic xenografts

(2009) P Cao et al.   BRITISH JOURNAL OF CANCER

Molecular Mechanisms Underlying Effects of Epidermal Growth Factor Receptor Inhibition on Invasion, Proliferation, and Angiogenesis in Experimental Glioma

(2009) J.-S. Guillamo et al.   CLINICAL CANCER RESEARCH

Antitumor activity of a novel antisense oligonucleotide against Akt1

(2009) Heejeong Yoon et al.   JOURNAL OF CELLULAR BIOCHEMISTRY

The EGFRvIII variant in glioblastoma multiforme

(2009) Hui K. Gan et al.   JOURNAL OF CLINICAL NEUROSCIENCE

Randomized Phase II Trial of Erlotinib Versus Temozolomide or Carmustine in Recurrent Glioblastoma: EORTC Brain Tumor Group Study 26034

(2009) Martin J. van den Bent et al.   JOURNAL OF CLINICAL ONCOLOGY

Imatinib in combination with hydroxyurea versus hydroxyurea alone as oral therapy in patients with progressive pretreated glioblastoma resistant to standard dose temozolomide

(2009) Gregor Dresemann et al.   JOURNAL OF NEURO-ONCOLOGY

Phase 2 trial of erlotinib plus sirolimus in adults with recurrent glioblastoma

(2009) David A. Reardon et al.   JOURNAL OF NEURO-ONCOLOGY

Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial

(2009) Roger Stupp et al.   LANCET ONCOLOGY

Therapeutic Inhibition of the Epidermal Growth Factor Receptor in High-Grade Gliomas: Where Do We Stand?

(2009) G. Karpel-Massler et al.   MOLECULAR CANCER RESEARCH

Inhibition of Akt inhibits growth of glioblastoma and glioblastoma stem-like cells

(2009) G. L. Gallia et al.   MOLECULAR CANCER THERAPEUTICS

Targeting the phosphoinositide 3-kinase pathway in cancer

(2009) Pixu Liu et al.   NATURE REVIEWS DRUG DISCOVERY

The pyridinylfuranopyrimidine inhibitor, PI-103, chemosensitizes glioblastoma cells for apoptosis by inhibiting DNA repair

(2009) M -A Westhoff et al.   ONCOGENE

Specific apoptosis induction by the dual PI3K/mTor inhibitor NVP-BEZ235 in HER2 amplified and PIK3CA mutant breast cancer cells

(2009) Saskia M. Brachmann et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Oncogenic EGFR Signaling Networks in Glioma

(2009) P. H. Huang et al.   Science Signaling

Effects of oncogenic p110α subunit mutations on the lipid kinase activity of phosphoinositide 3-kinase

(2008) Jeffrey D. Carson et al.   BIOCHEMICAL JOURNAL

Imidazo[4,5-c]quinolines as inhibitors of the PI3K/PKB-pathway

(2008) Frédéric Stauffer et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Characterization of an Akt Kinase Inhibitor with Potent Pharmacodynamic and Antitumor Activity

(2008) N. Rhodes et al.   CANCER RESEARCH

Mutations in the Phosphatidylinositol-3-Kinase Pathway Predict for Antitumor Activity of the Inhibitor PX-866 whereas Oncogenic Ras Is a Dominant Predictor for Resistance

(2008) N. T. Ihle et al.   CANCER RESEARCH

Epidermal growth factor receptor and glioblastoma multiforme: molecular basis for a new approach

(2008) Cristóbal Belda-Iniesta et al.   Clinical & Translational Oncology

Histone Deacetylase Inhibition and Blockade of the Glycolytic Pathway Synergistically Induce Glioblastoma Cell Death

(2008) V. Egler et al.   CLINICAL CANCER RESEARCH

Targeting the Epidermal Growth Factor Receptor in High-Grade Astrocytomas

(2008) Will R. Voelzke et al.   CURRENT TREATMENT OPTIONS IN ONCOLOGY

Correlation of O6-Methylguanine Methyltransferase (MGMT) Promoter Methylation With Clinical Outcomes in Glioblastoma and Clinical Strategies to Modulate MGMT Activity

(2008) Monika E. Hegi et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II study of carboplatin and erlotinib (Tarceva, OSI-774) in patients with recurrent glioblastoma

(2008) J. F. de Groot et al.   JOURNAL OF NEURO-ONCOLOGY

A pilot study of everolimus and gefitinib in the treatment of recurrent glioblastoma (GBM)

(2008) Teri N. Kreisl et al.   JOURNAL OF NEURO-ONCOLOGY

Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity

(2008) S.-M. Maira et al.   MOLECULAR CANCER THERAPEUTICS

Comprehensive genomic characterization defines human glioblastoma genes and core pathways

(2008) Roger McLendon et al.   NATURE

Progression-free survival: An important end point in evaluating therapy for recurrent high-grade gliomas

(2008) Kathleen R. Lamborn et al.   NEURO-ONCOLOGY

EGFRvIII expression and PTEN loss synergistically induce chromosomal instability and glial tumors

(2008) Li Li et al.   NEURO-ONCOLOGY

Malignant Gliomas in Adults

(2008) Patrick Y. Wen et al.   NEW ENGLAND JOURNAL OF MEDICINE

Helical domain and kinase domain mutations in p110  of phosphatidylinositol 3-kinase induce gain of function by different mechanisms

(2008) L. Zhao et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

An Integrated Genomic Analysis of Human Glioblastoma Multiforme

(2008) D. W. Parsons et al.   SCIENCE

Brain Cancer Stem Cells Display Preferential Sensitivity to Akt Inhibition

(2008) Christine E. Eyler et al.   STEM CELLS

Antitumor Activity of Rapamycin in a Phase I Trial for Patients with Recurrent PTEN-Deficient Glioblastoma

(2008) Tim F Cloughesy et al.   PLOS MEDICINE

PI3K/PTEN signaling in tumorigenesis and angiogenesis

(2007) Bing-Hua Jiang et al.   BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS